Friday, April 12, 2013

AREDS UPDATE

Five years after the clinical trial ended, the beneficial effects of the AREDS formulation persisted for development of neovascularization (wet macular degeneration) but not for geographic atrophy (dry macular degeneration). These results are consistent with the original recommendations that persons with intermediate or advanced AMD in 1 eye should consider taking the AREDS formulation.